Tanaka A, Mizoguchi H, Hase S, Miyazawa T, Takeuchi K
Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto, Japan.
Med Sci Monit. 2001 Sep-Oct;7(5):869-77.
We previously reported that lafutidine ((I)-2-(furfurylsulfinyl)-N-[4-[4-(piperidinomethyl)-2-pyridyl]oxy-(Z)-2-butenyl] acetamide), a novel histamine H(2)-receptor antagonist, protects the small intestine against indomethacin-induced damage, mediated by capsaicin-sensitive afferent neurons (CSN).
In the present study, we investigated whether or not the protective action of lafutidine against indomethacin-induced intestinal damage is mediated by endogenous nitric oxide (NO). Male SD rats were given indomethacin (10 mg/kg, s.c), killed 24 hr later, and the small intestinal mucosa was examined. Lafutidine (10 mg/kg) and capsaicin (10 mg/kg) was given p.o. twice 0.5 hr before and 9 hr after indomethacin. The NO synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME: 10 mg/kg) or the selective iNOS inhibitor aminoguanidine (10 mg/kg) was given s.c. 1 hr before lafutidine, while L-arginine (200 mg/kg) was given i.p. 10 min before L-NAME.
Indomethacin produced severe lesions in the small intestine, accompanied by increases in enterobacterial translocation in the mucosa. Both lafutidine and capsaicin significantly reduced the severity of these lesions, together with suppression of bacterial translocation. The protective action of lafutidine as well as capsaicin was almost totally abolished by L-NAME but not aminoguanidine, in a L-arginine-sensitive manner. Both lafutidine and capsaicin significantly increased intestinal mucus secretion, and these effects were also attenuated by prior administration of L-NAME. The exogenous NO donor NOR-3 prevented indomethacin-induced intestinal lesions at the dose that stimulated the mucus secretion and inhibited the bacterial translocation.
These results suggest that lafutidine protects the small intestine against indomethacin-induced damage, the action being dependent on CSN and mediated by endogenous NO produced by cNOS. The protective action of lafutidine may be attributable to suppression of the bacterial translocation following indomethacin, probably due to stimulation of intestinal mucus secretion.
我们之前报道过,新型组胺H₂受体拮抗剂拉呋替丁((I)-2-(糠基亚磺酰基)-N-[4-[4-(哌啶甲基)-2-吡啶基]氧基-(Z)-2-丁烯基]乙酰胺)可保护小肠免受吲哚美辛诱导的损伤,该损伤由辣椒素敏感传入神经元(CSN)介导。
在本研究中,我们调查了拉呋替丁对吲哚美辛诱导的肠道损伤的保护作用是否由内源性一氧化氮(NO)介导。给雄性SD大鼠皮下注射吲哚美辛(10 mg/kg),24小时后处死,检查小肠黏膜。在吲哚美辛给药前0.5小时和给药后9小时口服给予拉呋替丁(10 mg/kg)和辣椒素(10 mg/kg)。在拉呋替丁给药前1小时皮下注射NO合酶抑制剂N(G)-硝基-L-精氨酸甲酯(L-NAME:10 mg/kg)或选择性诱导型NO合酶抑制剂氨基胍(10 mg/kg),而在L-NAME给药前10分钟腹腔注射L-精氨酸(200 mg/kg)。
吲哚美辛导致小肠出现严重损伤,同时伴有黏膜内肠细菌移位增加。拉呋替丁和辣椒素均显著减轻了这些损伤的严重程度,并抑制了细菌移位。L-NAME几乎完全消除了拉呋替丁和辣椒素的保护作用,但氨基胍没有,且呈L-精氨酸敏感的方式。拉呋替丁和辣椒素均显著增加了肠道黏液分泌,预先给予L-NAME也减弱了这些作用。外源性NO供体NOR-3在刺激黏液分泌并抑制细菌移位的剂量下可预防吲哚美辛诱导的肠道损伤。
这些结果表明,拉呋替丁可保护小肠免受吲哚美辛诱导的损伤,其作用依赖于CSN,并由组成型NO合酶产生的内源性NO介导。拉呋替丁的保护作用可能归因于抑制了吲哚美辛后的细菌移位,这可能是由于刺激了肠道黏液分泌。